Our investigation posited that CKS2 may play a pivotal role in the pathogenesis of BL and DLBCL, presenting compelling evidence to support the potential synergistic efficacy of combining CKS2‐shRNA with etoposide in therapeutic strategies targeting these malignancies. This evidence concerns the gene CKS2 and Burkitt lymphoma.